CN Patent

CN114828889B — 用于治疗结节性硬化症的加奈索酮

Assigned to Imeldica Pharmaceuticals Usa Inc · Expires 2025-02-14 · 1y expired

What this patent protects

本公开涉及用于治疗结节性硬化症或结节性硬化症相关癫痫的方法，所述方法包括向有需要的受试者施用治疗有效量的药学上可接受的孕烯醇酮神经类固醇，诸如加奈索酮，以减轻结节性硬化症或结节性硬化症相关癫痫的一种或多种症状。

USPTO Abstract

本公开涉及用于治疗结节性硬化症或结节性硬化症相关癫痫的方法，所述方法包括向有需要的受试者施用治疗有效量的药学上可接受的孕烯醇酮神经类固醇，诸如加奈索酮，以减轻结节性硬化症或结节性硬化症相关癫痫的一种或多种症状。

Drugs covered by this patent

Patent Metadata

Patent number: CN114828889B
Jurisdiction: CN
Classification: —
Expires: 2025-02-14
Drug substance claim: No
Drug product claim: No
Assignee: Imeldica Pharmaceuticals Usa Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.